Format
Sort by

Send to:

Choose Destination

Results: 5

Cited In for PubMed (Select 15955889)

1.

Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.

Wen J, Zhao Y, Li J, Weng C, Cai J, Yang K, Yuan H, Imperato-McGinley J, Zhu YS.

Prostate. 2013 Jul;73(10):1069-81. doi: 10.1002/pros.22654. Epub 2013 Feb 19.

2.

Differential effects of estrogen receptor ligands on regulation of dihydrotestosterone-induced cell proliferation in endothelial and prostate cancer cells.

Weng C, Cai J, Wen J, Yuan H, Yang K, Imperato-McGinley J, Zhu YS.

Int J Oncol. 2013 Jan;42(1):327-37. doi: 10.3892/ijo.2012.1689. Epub 2012 Nov 6.

3.

Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.

Qiao Y, Wang L, Cai LQ, Tan C, Imperato-McGinley J, Zhu YS.

J Urol. 2011 Jan;185(1):305-14. doi: 10.1016/j.juro.2010.09.008.

4.

17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.

Qiao Y, Zhang ZK, Cai LQ, Tan C, Imperato-McGinley JL, Zhu YS.

Prostate. 2007 Dec 1;67(16):1719-28.

5.

Molecular Basis of Steroid Action in the Prostate.

Zhu YS.

Cellscience. 2005 Apr 28;1(4):27-55. No abstract available.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk